Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 346Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 8Trerief/Excegran

02 5Zonegran

PharmaCompass

01

Brand Name : Zonegran

Zonisamide

arrow
Antibody Engineering
Not Confirmed

Brand Name : Zonegran

arrow
Antibody Engineering
Not Confirmed

Zonisamide

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 44

2019 Revenue in Millions : 43

Growth (%) : 2

blank

02

Brand Name : Trerief/Excegran

Zonisamide

arrow
Antibody Engineering
Not Confirmed

Brand Name : Trerief/Excegran

arrow
Antibody Engineering
Not Confirmed

Zonisamide

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 157

2019 Revenue in Millions : 155

Growth (%) : 1

blank

03

Brand Name : Trerief/Excegran

Zonisamide

arrow
Antibody Engineering
Not Confirmed

Brand Name : Trerief/Excegran

arrow
Antibody Engineering
Not Confirmed

Zonisamide

Main Therapeutic Indication : Neurology

Currency : USD

2021 Revenue in Millions : 138

2020 Revenue in Millions : 157

Growth (%) : 1

blank

04

Brand Name : Zonegran

Zonisamide

arrow
Antibody Engineering
Not Confirmed

Brand Name : Zonegran

arrow
Antibody Engineering
Not Confirmed

Zonisamide

Main Therapeutic Indication : Neurology

Currency : USD

2021 Revenue in Millions : 33

2020 Revenue in Millions : 42

Growth (%) : -15

blank

05

Brand Name : Trerief/Excegran

Zonisamide

arrow
Antibody Engineering
Not Confirmed

Brand Name : Trerief/Excegran

arrow
Antibody Engineering
Not Confirmed

Zonisamide

Main Therapeutic Indication : Neurology

Currency : USD

2022 Revenue in Millions : 128

2021 Revenue in Millions : 138

Growth (%) : -8

blank

06

Brand Name : Trerief/Excegran

Zonisamide

arrow
Antibody Engineering
Not Confirmed

Brand Name : Trerief/Excegran

arrow
Antibody Engineering
Not Confirmed

Zonisamide

Main Therapeutic Indication : Neurology

Currency : USD

2023 Revenue in Millions : 113

2022 Revenue in Millions : 128

Growth (%) : 1

blank

07

Brand Name : Trerief/Excegran

Zonisamide

arrow
Antibody Engineering
Not Confirmed

Brand Name : Trerief/Excegran

arrow
Antibody Engineering
Not Confirmed

Zonisamide

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2016 Revenue in Millions : 132

2015 Revenue in Millions : 120

Growth (%) : 11

blank

08

Brand Name : Trerief/Excegran

Zonisamide

arrow
Antibody Engineering
Not Confirmed

Brand Name : Trerief/Excegran

arrow
Antibody Engineering
Not Confirmed

Zonisamide

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2017 Revenue in Millions : 161

2016 Revenue in Millions : 150

Growth (%) : 8

blank

09

Brand Name : Trerief/Excegran

Zonisamide

arrow
Antibody Engineering
Not Confirmed

Brand Name : Trerief/Excegran

arrow
Antibody Engineering
Not Confirmed

Zonisamide

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2018 Revenue in Millions : 140

2017 Revenue in Millions : 145

Growth (%) : -3%

blank

10

Brand Name : Zonegran

Zonisamide

arrow
Antibody Engineering
Not Confirmed

Brand Name : Zonegran

arrow
Antibody Engineering
Not Confirmed

Zonisamide

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2017 Revenue in Millions : 43

2016 Revenue in Millions : 53

Growth (%) : -18

blank